📝 Fermenta Biotech Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
Fermenta Biotech Ltd reported revenue of ₹122 crore for the quarter ended June 2026 (Q1 FY27), down 10.4% from ₹136 crore in the same quarter last year, and down 0.1% sequentially over the March 2026 quarter.
Net profit fell 56.7% year-on-year to ₹10 crore, from ₹22 crore. Earnings per share (EPS) came in at ₹3.31.
Operating profit stood at ₹18 crore — an operating margin (OPM) of 14.8%, compared with 20.6% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Fermenta Biotech Ltd posted revenue of ₹525 crore, a growth of 11.9% over FY25, with a net profit of ₹71 crore (down 6.6% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹511 crore with a net profit of ₹59 crore.
Valuation snapshot
At the current price of ₹468.85, 506414 has a market capitalisation of ₹1,313 crore and a trailing P/E of about 22.4.
Within the Pharmaceuticals industry, it is the 7th-largest of the 82 companies we track by market value.
Shareholding pattern
As of Mar 2026, promoters held 64.08%, foreign institutional investors (FIIs) 0.02%, public shareholders 33.32% of Fermenta Biotech Ltd.